OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Barata on Immunotherapy Treatment and the Gut Microbiome in Kidney Cancer

August 25th 2023

Pedro Barata, MD, MSc, discusses important considerations regarding the relationship between immunotherapy treatment and the gut microbiome when treating patients with kidney cancer.

Dr Goetz on Post-CDK4/6 Inhibitor Treatment Options in HR-Positive Breast Cancer

August 25th 2023

Matthew P. Goetz, MD, discusses the available treatment options for patients with metastatic hormone receptor–positive breast cancer in the post-CDK inhibitor setting.

Dr Kremyanskaya on the Safety of Rusfertide in Phlebotomy-Dependent PV

August 25th 2023

Marina Kremyanskaya, MD, PhD, discusses the safety profile and future implications of rusfertide in the treatment of patients with phlebotomy-dependent polycythemia vera, as seen in the phase 2 REVIVE trial.

Dr Vaishampayan on the Use of Talazoparib and Enzalutamide in Patients With HRR Gene–Mutated mCRPC

August 24th 2023

Ulka Nitin Vaishampayan, MBBS, discusses the need for improved identification of patients with homologous recombination repair (HRR) gene–mutated metastatic castration-resistant prostate cancer who may benefit from treatment with talazoparib and enzalutamide.

Dr Williams on Eye Toxicities Associated With ADCs in Ovarian Cancer

August 24th 2023

Heather R. Williams, MD, discusses ocular toxicities associated with antibody-drug conjugates and strategies for managing these toxicities in patients with ovarian cancer.

Dr. Ramaswamy on the Real-World Data Implications of Palbociclib in HR-Positive Breast Cancer

August 24th 2023

Bhuvaneswari Ramaswamy, MD, discusses the importance of real-world data when considering the efficacy of the CDK 4/6 inhibitor palbociclib in hormone receptor–positive breast cancer.

Dr Mead on the Decreased Use of Ibrutinib in Pretreated MCL

August 24th 2023

Monica D. Mead, MD, discusses reasons for the declining use of the BTK inhibitor ibrutinib in patients with mantle cell lymphoma.

Dr Kalemkerian on Unmet Needs With the Use of Chemoimmunotherapy in ES-SCLC

August 24th 2023

Gregory Peter Kalemkerian, MD, discusses the unmet needs associated with the investigation of combination chemoimmunotherapy in the frontline treatment of patients with extensive-stage small cell lung cancer.

Dr Kremyanskaya on the Promise of Rusfertide in Phlebotomy-Dependent PV

August 24th 2023

Marina Kremyanskaya, MD, PhD, discusses the potential advantages of using rusfertide to treat patients with phlebotomy-dependent polycythemia vera, as seen in the phase 2 REVIVE trial.

Dr Petrylak on Sequencing Questions in FGFR2/3-Altered Metastatic Urothelial Cancer

August 24th 2023

Daniel P. Petrylak, MD, discusses sequencing treatment selections in patients with FGFR2/3-altered metastatic urothelial cancer.

Dr Reichert on Investigating Novel Agents and Pathways in Prostate Cancer

August 23rd 2023

Zachery Roger Reichert, MD, PhD, discusses the effects novel agents and pathways have had on the treatment of patients with prostate cancer.

Dr Hammers on Ongoing Investigations in Advanced RCC

August 23rd 2023

Hans Hammers, MD, PhD, discusses ongoing and planned investigations with the use of HIF2α inhibitors and triplet therapies in patients with advanced renal cell carcinoma.

Dr Hamilton on the Use of ADCs in Breast Cancer

August 23rd 2023

Erika P. Hamilton, MD, discusses the use and sequencing of antibody-drug conjugates in patients with hormone receptor-positive/HER2-negative and HER2-low breast cancer.

Dr Amengual on Tazemetostat, Lenalidomide, and Rituximab in Relapsed/Refractory FL

August 23rd 2023

Jennifer Effie Amengual, MD, discusses considerations for community oncologists looking to refer patients with relapsed/refractory follicular lymphoma (FL) to the ongoing second-line, phase 3 SYMPHONY-1 trial (NCT04224493).

Dr Hansford on the FIREFLY-1 Trial of Tovorafenib in Pediatric Low-Grade Glioma

August 23rd 2023

Jordan Hansford, MD, discusses the phase 2 FIREFLY-1 trial, which is investigating the pan-RAF inhibitor tovorafenib (DAY101) in children and young adults with low-grade glioma.

Dr Cannon on the Investigation of the Th17 Dendritic Cell Vaccine in Ovarian Cancer

August 23rd 2023

Martin Cannon, PhD, discusses the phase 1 investigation of the Th17 dendritic cell vaccine in ovarian cancer, and how it could potentially improve suboptimal responses when treated with immunotherapy alone in this population.

Dr Mead on the Shifting Role of Ibrutinib in the Treatment of MCL

August 23rd 2023

Monica D. Mead, MD, discusses the impact of key data on the role of ibrutinib in the treatment of mantle cell lymphoma.

Dr Sonpavde on the Importance of Utilizing Precision Medicine in Bladder Cancer

August 22nd 2023

Guru P. Sonpavde, MD, discusses the importance of utilizing precision medicine in bladder cancer, and highlights the rationales and designs of the ongoing phase 3 EV-302 and AMBASSADOR trials.

Dr Tarantino on the Use of ADCs in HR+ Breast Cancer

August 22nd 2023

Paolo Tarantino, MD, discusses the use of antibody drug conjugates in patients with hormone receptor-positive breast cancer.

Dr Alumkal on Triplet Therapy in Prostate Cancer

August 22nd 2023

Joshi Alumkal, MD, discusses the use of triplet therapy in prostate cancer.